Cereno Scientific announces that Redeye initiates equity research coverage of company

Cereno Scientific (XSAT: CRNO B) today announced that Redeye has been engaged by Cereno to produce regular, in-depth equity research reports on the company. The primary purpose is to raise the visibility of Cereno as well as enable investors and shareholders to develop an improved understanding of the business.

Redeye is specialized on innovative and Nordic companies within Life Science and Technology. The initial coverage report is now published and available on Cereno’s website, www.cerenoscientific.com, as well as on Redeye’s website, www.redeye.se/company/cereno-scientific.

For further information, please contact:

Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study for CS1 in PAH is expected to be initiated in September 2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.